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Abstract
Coeliac disease is characterized by intestinal inﬂammation caused by gluten, proteins which are widely contained in the Western diet.
Mammalian digestive enzymes are only partly capable of cleaving gluten, and fragments remain that induce toxic responses in patients with
coeliac disease. We found that the oral microbiome is a novel and rich source of gluten-degrading organisms. Here we report on the
isolation and characterization of the cultivable resident oral microbes that are capable of cleaving gluten, with special emphasis on the
immunogenic domains. Bacteria were obtained by a selective culturing approach and enzyme activities were characterized by: (i) hydrolysis
of paranitroanilide-derivatized gliadin-derived tripeptide substrates; (ii) gliadin degradation in-gel (gliadin zymography); (iii) gliadin
degradation in solution; (iv) proteolysis of the highly immunogenic a-gliadin-derived 33-mer peptide. For selected strains pH activity proﬁles
were determined. The culturing strategy yielded 87 aerobic and 63 anaerobic strains. Species with activity in at least two of the four assays
were typed as: Rothia mucilaginosa HOT-681, Rothia aeria HOT-188, Actinomyces odontolyticus HOT-701, Streptococcus mitis HOT-677,
Streptococcus sp. HOT-071, Neisseria mucosa HOT-682 and Capnocytophaga sputigena HOT-775, with Rothia species being active in all four
assays. Cleavage speciﬁcities and substrate preferences differed among the strains identiﬁed. The approximate molecular weights of the
enzymes were ~75 kD (Rothia spp.), ~60 kD (A. odontolyticus) and ~150 kD (Streptococcus spp.). In conclusion, this study identiﬁed new
gluten-degrading microorganisms in the upper gastrointestinal tract. A cocktail of the most active oral bacteria, or their isolated enzymes,
may offer promising new treatment modalities for coeliac disease.
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Introduction
Coeliac disease is an inﬂammatory disorder with autoimmune
features and a primary manifestation in the human small
intestine. The disease is triggered upon ingestion of wheat
gluten or similar proteins found in barley and rye (mainly
hordeins and secalins, respectively). Gluten, comprising glute-
nins and gliadins, contain a relatively high concentration of
glutamine and proline residues within their structures [1,2],
endowing certain gluten-derived domains with high resistance
to degradation by human gastrointestinal proteases. None of
the major human gastrointestinal proteases, such as pepsin,
trypsin, chymotrypsin, carboxypeptidases A and B, elastases and
brush-border membrane enzymes of the small intestine contain
the necessary proteolytic capabilities to effectively cleave
certain immunogenic gluten peptides, because of a lack of
post-proline cleavage-site speciﬁcity. An example of a gliadin-
derived, human intestinal protease-resistant peptide is the
33-mer peptide derived from a-gliadins (LQLQPFPQPQLP
YPQPQLPYPQPQLPYPQPQPF) [3]. Apart from its resistance
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to proteolysis, it contains multiple, in part overlapping, immu-
nogenic epitopes which stimulate CD4+ T cells in the lamina
propria of HLA-DQ2-positive patients with coeliac disease [4].
In most patients adherence to a gluten-free diet reverses
the immune-mediated small intestinal damage and fully
restores absorptive functions, whereas reintroduction of
dietary gluten leads to renewed disease [5]. However, to
completely exclude even traces of gluten from the daily diet is
a difﬁcult task, as gluten is an abundant constituent of most
reﬁned foods. In addition, there are other complicating factors
such as cross-contamination of foods and inadequate food
labelling. Finally, the necessity for leading a strict gluten-free life
(as opposed to a diet that only excludes obvious and major
sources of gluten such as bread, pizza or pasta) means a socio-
economic burden for the patient. Therefore, alternative or
adjunctive treatments beyond the strict gluten-free diet are
considered an area of therapeutic need [6].
To achieve a more complete digestion of gluten, and
speciﬁcally its immunogenic domains, proline-speciﬁc and
glutamine-speciﬁc endopeptidases from bacteria, fungi and
barley are currently being explored, and such therapies are in
phase I–II clinical studies [7–13]. Notably, research in our
laboratory has recently shown that gluten-degrading proteases
are naturally present in the upper human gastrointestinal tract.
These enzymes are not of human origin, but are produced by
the wealth of bacteria that colonize the oral cavity and
duodenum [14,15]. Here we performed a large-scale screening
of the cultivable portion of the human oral microbiome for
bacteria with proteolytic enzymes cleaving any of ﬁve selected
gliadin-derived synthetic tripeptide enzyme substrates, intact
gliadins, and the immunodominant a-gliadin 33-mer peptide.
Such bacteria could possibly fulﬁl physiological roles in the
digestion of gluten in vivo. Moreover, they may serve as a safe
source of enzyme(s) with clinical potential in the treatment of
gluten sensitivity and coeliac disease.
Materials and Methods
Collection of dental plaque and whole saliva
Protocols for the collection of human dental plaque and whole
saliva were approved by the Institutional Review Board at
Boston University. Written informed consent was obtained
from the participating subject before sample collection.
Samples were collected after the donor had refrained from
oral hygiene for 24 h. Plaque was collected using a sterile
dental scaler and suspended in a buffer mimicking the ion
composition of saliva, containing 50 mM KCl, 1.5 mM potas-
sium phosphate, 1 mM CaCl2 and 0.1 mM MgCl2, pH 7.0.
Bacterial aggregates were resuspended with a pipette. Whole
saliva was collected under conditions of masticatory stimula-
tion as described previously [15].
Culturing of bacteria
Dental plaque and whole saliva suspensions were diluted 103,
104 and 105 times in saliva ion buffer. Aliquots of 50 lL were
plated either on Brucella agar (Hardy Diagnostics, Santa Maria,
CA, USA) or on gluten-limited agar, which was prepared
in-house [15]. Plates were incubated aerobically or anaerobi-
cally in a jar using GasPak pouches (BD Diagnostics, Sparks,
MD, USA) at 37°C for 24–72 h. Individual colonies were
subcultured on segmented gluten agar or Brucella agar,
respectively, with up to 20 strains per plate. Colonies were
then subcultured repeatedly on Brucella agar (one strain per
plate) to obtain macroscopically pure cultures. The ﬁnal pure
strains were plated on gluten agar to conﬁrm their growth
on this selective medium. The bacterial strains were main-
tained frozen in a mixture of Brain–Heart infusion/glycerol
(80/20% v/v).
16S rDNA identiﬁcation of bacteria
DNA extraction from colonies grown on Brucella agar was
performed using the UltraClean Microbial DNA Isolation Kit
(Mo Bio Laboratories, Carlsbad, CA, USA) followed by
sequencing using an ABI prism cycle-sequencing kit (BigDye
Terminator Cycle Sequencing kit) as previously described [16].
Hydrolysis of gliadin-derived enzyme substrates
Cells were harvested with a sterile cotton swab from Brucella
agar plates and resuspended in saliva ion buffer to an optical
density at 620 nm (OD620) of 1.2. Enzymatic activity was
examined towards ﬁve gliadin-derived synthetic enzyme sub-
strates: Z-YPQ-pNA, Z-QQP-pNA, Z-PPF-pNA, Z-PFP-pNA
andZ-LPY-pNA. The tripeptide substrates represent sequences
that are common in the immunogenic gliadin domains. Sub-
strates were mixed with 200 lL bacterial suspensions (OD620
1.2) to a ﬁnal concentration of 200 lM and incubated at 37°C.
For initial screening of bacteria for substrate hydrolysis, data
were interpretedmacroscopically over a 48 h time interval with
assessment time-points of 1, 16, 24, 40 and 48 h. Kinetic enzyme
assays were carried out for selected strains, measuring
substrate hydrolysis at 405 nm using a Genios microtitre plate
reader (Tecan, M€annedorf, Switzerland).
Degradation of gliadin in-gel (gliadin zymography)
Cells were harvested with a cotton swab from Brucella agar
plates and suspended in saliva ion buffer to an OD620 of 5.0.
Cells contained in a 150-lL aliquot were centrifuged and
suspended in zymogram sample buffer containing 0.25 M
Tris–HCl, 10% glycerol, 2% SDS and 0.0025% bromophenol
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blue. Gliadin zymography (6%) was carried out as described
previously [15]. Gels were processed in renaturing and
developing buffers (Invitrogen, Carlsbad, CA, USA) according
to the manufacturer’s instructions. After 48 h of incubation at
37°C, gels were stained in 0.2% Coomassie Brilliant blue
dissolved in 40% methanol and destained without the dye.
Degradation of gliadin in solution
A mixture of gliadins obtained from Sigma (St Louis, MO, USA)
was dissolved to 5 mg/mL in 60% (v/v) ethanol. The solution
was diluted in bacterial cell suspensions in saliva ion buffer
(OD620 1.2) to 250 mg/L. After incubation for 0, 2 and 5 h at
37°C, 100-lL aliquots were removed and boiled for 5 min to
inactivate enzyme activity. For some strains different time-
points and cell densities were used (noted in the legends of
Figs 2, S1 and S2c). To each sample aliquot, EDTA was added
to a ﬁnal concentration of 2.5 mM to complex calcium ions in
the saliva ion buffer, and samples were dried using a Speedvac.
Pellets were suspended in 1 9 SDS sample buffer and analysed
on pre-cast 12% Bis–Tris–PAGE (Invitrogen).
Degradation of the 33-mer gliadin peptide
A synthetic highly immunogenic 33-mer peptide derived from
a2-gliadin (LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF)
[3] was synthesized at 21st Century Biochemicals (Marlboro,
MA, USA) at a purity of 95%. The peptide was dissolved in
milliQ water at 10 mg/mL and diluted to 250 mg/L in bacterial
cell suspensions (OD620 1.2). Incubations, sample aliquot
removal and heat-inactivation of the enzymes were carried
out as in the gliadin degradation experiment. The 100-lL
aliquots were mixed with 900 lL 0.1% triﬂuoroacetic acid and
subjected to reversed phase-HPLC using a C-18 column (TSK-
GEL 5 lm, ODS-120T, 4.6 9 250 mm, TOSOHaas, Mont-
gomeryville, PA, USA). Peptides were eluted using a multi-step
gradient as described previously [14].
Enzyme activities at various pH values
To assess the bacterial enzyme activities at various pH, three
select strains were suspended to an OD620 1.2 in 20 mM Tris
solutions at pH 3.0, 5.0, 7.0 or 9.0. Activities were assessed
towards Z-YPQ-pNA as the enzyme substrate (200 lM) with
a Genios microtitre plate reader in the kinetic mode over an 8-
h time interval.
In another experiment, equal volumes of suspensions of the
same three strains, each at an OD620 1.2, were mixed. The
mixture was then divided into three portions. The pH of the
ﬁrst two aliquots was adjusted to pH 3.0 with HCl, the third
aliquot was adjusted to pH 7.0 with concentrated sodium
bicarbonate. The pH of the second aliquot at pH 3.0 was
adjusted to pH 7.0 after a 1.5-h incubation time interval at
37°C. Enzyme activities in all three aliquots were determined
spectrophotometrically using Z-YPQ-pNA.
Results
Hydrolysis of gliadin-derived enzyme substrates
Using the selective plating approach, 87 aerobic strains and
63 anaerobic strains were obtained. Among the 87 aerobic
strains 16 were isolated from human whole saliva (referred
to as WSA-#) and 71 from human dental plaque (referred to
as PA-#). Among the 63 anaerobic strains 18 were derived
from whole saliva and 45 were from dental plaque. To
evaluate enzymatic cleavage speciﬁcities, the 87 aerobic
strains were incubated with gliadin-derived synthetic enzyme
substrates and hydrolysis was monitored macroscopically. As
this assay was intended for screening purposes only, exper-
iments were performed once, and repeated for select strains
that showed activity. Of the 87 aerobic strains, 75 cleaved
Z-YPQ-pNA, 7 cleaved Z-QQP-pNA, 5 cleaved PPF-pNA, 8
cleaved Z-PFP-pNA and 52 cleaved Z-LPY-pNA (see Supple-
mentary material, Table S1). Of the 75 strains hydrolysing
Z-YPQ-pNA, 12 hydrolysed this substrate within 1 h of
incubation. All strains that cleaved Z-LPY-pNA also cleaved
Z-YPQ-pNA, but not the reverse. Lastly, ﬁve strains rapidly
hydrolysed all ﬁve substrates within 1 h of incubation. The
anaerobic strains tested (35 out of 63 strains) did not cleave
any of the ﬁve tripeptide substrates and were not further
considered.
Zymography results
To determine gliadin degradation in gel, the 87 aerobic
bacteria were subjected to gliadin zymography. A total of 15
strains showed the presence of gliadin-degrading enzyme(s),
either in the ~60 kDa, ~75 kDa, or ~150 kDa region. The
remainder of the strains did not show evidence of gliadin
degrading activity in gel (see Supplementary material, Table
S2). Taking the tripeptide hydrolysis and the zymogram results
together, 21 aerobic strains were deemed of interest and
categorized into ﬁve groups based on their patterns of activity.
Group I (n = 5): YPQ↓ and LPY↓ cleavage and an enzyme with
a molecular weight of ~75 kDa; group II (n = 1): YPQ↓ and
LPY↓ cleavage and an enzyme at ~60 kDa; group III (n = 9):
YPQ↓ cleavage and a weak enzyme band at ~150 kDa; group
IV (n = 2): YPQ↓, QQP↓, and LPY↓ cleavage but no evidence
for activity in the gliadin zymogram, and group V (n = 5):
cleaveage of YPQ↓, QQP↓, PPF↓, PFP↓ and LPY↓ and no band
in the gliadin zymogram gel (Table 1).
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16S rDNA sequencing results
The 21 strains of interest were identiﬁed to species by 16S
rDNA analysis. As expected, in some cases, strains within one
group represented the same species. A clear picture emerged
as to the differences in species in the ﬁve groups. The taxa
identiﬁed in group I were: Rothia mucilaginosa HOT-681 and
Rothia aeria HOT-188; in group II: Actinomyces odontolyticus
HOT-701; in group III: Streptococcus mitis HOT-677 and
Streptococcus sp. HOT-071; in group IV: Neisseria mucosa
HOT-682; and in group V: Capnocytophaga sputigena HOT-775
(Table 1). A representative zymogram with a selection of
strains from each group is shown in Fig. 1.
Degradation of gliadin in solution
A subset of strains was selected to study their capacity to
degrade gliadin in solution. These were three strains from
Group I (WSA-2B, WSA-21B, WSA-26), one strain from
group II (PA-20b), four strains from group III (PA-12, PA-21,
PA-3b, and PA-19b), two strains from group IV (PA-1b, PA-2b)
and two strains from group V (PA-33R, PA-90R). Results
obtained with R. aeria (strain WSA-8) were reported previ-
ously [15]. The ﬁnal OD620 and incubation times for strains in
groups I, II and III were OD620 1.2 and 0, 2 h and 5 h,
respectively, and for strains in group IV and V the OD620 was
0.2 and the incubation times were 0, 4 and 8 h, respectively.
The OD and time adjustment were made based on the
apparent high protein content in these strains (see Fig. 1).
Only bacteria in group I cleaved gliadin in solution (see
Supplementary material, Figure S1). Results for strains WSA-
2B (group I), PA-20b (group II) and PA-33R (group V) are
shown in Fig. 2, left panels.
Degradation of the 33-mer gliadin peptide
The same 12 strains were also investigated for degrading
the gliadin-derived 33-mer peptide. The cell densities and
TABLE 1. Summary evaluation of aerobic strainsa
pNA-derivatized tripeptide substrates
Strain name Strain ID# YPQ QQP PPF PFP LPY
Gliadin zymo
band (MW)
Gliadin degradation
in solution
33-mer
degradation
GROUP I
Rothia mucilaginosa HOT-681 WSA-2B +1 h – – – +16 h ~70/75 kD Yes Yes
Rothia sp. HOT-188 (Rothia aeria) WSA-8 +1 h – – – +16 h ~75 kD Yes Yes
Rothia mucilaginosa HOT-681 WSA-21B +1 h – – – +16 h ~70/75 kD Yes 
Rothia mucilaginosa HOT-681 WSA-26 +1 h – – – +16 h ~70/75 kD Yes Yes
GROUP II
Actinomyces odontolyticus HOT-701 PA-20b +1 h – – – +16 h ~60 kD No Yes
GROUP III
Streptococcus mitis HOT-677 WSA-7A +16 h – – – – ~150 kD n.d. n.d.
Streptococcus mitis HOT-677 PA-8 +16 h – – – – ~150 kD n.d. n.d.
Streptococcus sp. HOT-071 PA-9 +16 h – – – – ~150 kD n.d. n.d.
Streptococcus mitis HOT-677 PA-12 +16 h – – – – ~150 kD No No
Streptococcus sp. HOT-071 PA-21 +24 h – – – – ~150 kD No No
Streptococcus sp. HOT-071 PA-3b +16 h – – – – ~150 kD No No
Streptococcus sp. HOT-071 PA-4b +16 h – – – – ~150 kD n.d. n.d.
Streptococcus mitis HOT-677 PA-19b +24 h – – – – ~150 kD No No
Streptococcus sp. HOT-071 PA-23b +24 h – – – – ~150 kD n.d. n.d.
GROUP IV
Neisseria mucosa HOT-682 PA-1b +1 h 24 h – – +16 h – n.d. n.d.
Neisseria mucosa HOT-682 PA-2b +1 h 24 h – – +16 h – No No
GROUP V
Capnocytophaga sputigena HOT-775 PA-33B +1 h +1 h +1 h +1 h +1 h – n.d. n.d.
Capnocytophaga sputigena HOT-775 PA-33R +1 h +1 h +1 h +1 h +1 h – No Yes
Capnocytophaga sputigena HOT-775 PA-90B +1 h +1 h +1 h +1 h +1 h – n.d. n.d.
Capnocytophaga sputigena HOT-775 PA-90R +1 h +1 h +1 h +1 h +1 h – No Yes
Capnocytophaga sputigena HOT-775 PA-90 +1 h +1 h +1 h +1 h +1 h – n.d. n.d.
aTotal number of aerobic bacteria screened: 87; total number of bacteria cleaving one or more of the ﬁve tripeptide-pNA substrates: 78.
+: colour change due to substrate hydrolysis, occurring after the indicated incubation time (macroscopic assessment), gliadin and 33-mer degradation in solution: 250 mg/L
protein, proteolysis assessed by SDS–PAGE and reversed phase-HPLC, respectively.
FIG. 1. Gliadin zymography of selected oral strains: 150-ll aliquots
of cells (OD620 5.0) were applied per lane. Lane 1, WSA-2B (Rothia
mucilaginosa); lane 2: WSA-8 (Rothia aeria); lane 3: WSA-21B
(R. mucilaginosa); lane 4: PA-20b (Actinomyces odontolyticus); lane 5:
PA-12 (Streptococcus mitis); lane 6: PA-21 (Streptococcus sp. HOT-
071); lane 7: PA-2b (Neisseria mucosa); lane 8: PA-90R (Capnocytoph-
aga sputigena).
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incubation times used were the same as for the gliadin
degradation experiments. Fig. S2A–C show the chromato-
grams obtained (see Supplementary material). Strains in group
I (R. mucilaginosa HOT-681) cleaved the 33-mer partly in the
5-h time span and buffer conditions examined. The strain in
group II (A. odontolyticus HOT-701) cleaved the 33-mer
completely within a 2-h time interval, with proteolysis already
noticeable in the t = 0 sample (taken immediately after mixing
of the 33-mer peptide with PA-20b suspension). The degra-
dation patterns at t = 2 h and t = 5 h were comparable, and
remained stable over a 24-h time span (not shown). Strains in
groups III (S. mitis HOT-677 and Streptococcus HOT-071) and
IV (N. mucosa HOT-682) were unable to cleave the 33-mer
peptide. In contrast, group V bacteria (C. sputigena HOT-775)
cleaved the 33-mer rapidly without any visible evidence for
surviving major degradation fragments. Results for strains
WSA-2B, PA-20b and PA-90R are shown in Fig. 2, right panels.
Table 1 summarizes all the results obtained.
pH activity proﬁles
Three strains with prominent activities were selected for pH
activity determinations: WSA-21B (R. mucilaginosa HOT-681),
(a)
(b)
(c)
FIG. 2. Kinetics of gliadin degradation and 33-mer degradation by WSA-2B, PA-20b and PA-90R. Arrows point to the major protein component in
the gliadin preparation at ~37 kD (SDS gels, left panels) and the 33-mer (RP-HPLC chromatograms, right panels). The cell densities used for the
incubations were OD620 1.2 for WSA-2B and PA-20b and OD620 0.2 for PA-90R. The ﬁnal concentration of mixed gliadins and 33-mer peptide were
250 lg/ml. Degradation mixtures were analysed at t = 0, 2 h and 5 h (strains WSA-2B and PA-20b) and t = 0, 4 h and 8 h (strain PA90R).
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PA-20b (A. odontolyticus HOT-701) and PA-90R (C. sputigena
HOT-775). Enzymatic activities for all three strains were
optimal at neutral to basic pH conditions. At pH 5.0, rates of
hydrolysis were reduced for all strains and at pH 3.0 none of
the strains were active over the 8-h time interval examined
(Fig. 3). The latter would suggest that the strains are not
active at the pH conditions encountered in the fasting
stomach. To investigate if the strains could withstand low
pH conditions for a time interval consistent with gastric
passage, we performed an experiment in which a mixture of
the three strains was incubated at pH 3.0 for 1.5 h, after
which the pH was adjusted to pH 7.0. Enzyme activity
assessment conﬁrmed activity of the bacterial mixture at pH
7.0 and inactivity at pH 3.0. Importantly, bacteria preincu-
bated at pH 3.0 were not irreversibly inactivated, as their
activity could be fully restored when the pH was adjusted to
pH 7.0.
Discussion
This study was aimed at the discovery and broad character-
ization of natural resident microbes in the uppermost part of
the gastrointestinal tract that can degrade the immunogenic
gliadins implicated in coeliac disease. The approach consisted
of a culture-based initial enrichment step for such bacteria
from the mixed bacterial oral samples. Enzyme activities
associated with the isolates were determined in four inde-
pendent assays. Bacteria could be separated into ﬁve groups
after analysing degradation patterns and bacterial IDs. The
most active microbes were tested at various pH, showing that
their enzymes were not active at acidic pH, but that a
temporary exposure to a low pH consistent with gastric
transfer was permissible. Additional information on the
identiﬁed strains’ rank of abundance in the oral cavity, and
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FIG. 3. pH gluten peptide degrading activity proﬁles of WSA-21B, PA-20b and PA-90R. Strains were suspended to a ﬁnal OD620 1.2 in Tris solutions
with pH values adjusted to pH 3.0, 5.0, 7.0 and 9.0, and hydrolysis of Z-YPQ-pNA (ﬁnal concentration 200 lM) was monitored
spectrophotometrically at 405 nm over a 0–480 min time interval. (a) WSA-21B; (b) PA-20b; (c) PA-90R. (d) Equal volumes of the three strains
were mixed at pH 3.0, pH 7.0, or at pH 3.0 followed by adjustment of the pH after 1.5 h to 7.0. Z-YPQ-pNA hydrolysis in the three suspensions is
shown.
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the number of known and putative peptidases, are given in
Table 2.
Bacteria in Group I comprised R. mucilaginosa HOT-681 and
R. aeria HOT-188. Both strains were active in all four assays
and therefore are of strong interest. Rothia species are
harmless residents of the oral cavity and the oral pharynx
[16], and have also been identiﬁed in duodenal biopsies [17].
There are case reports of infections caused by R. mucilaginosa
in immunocompromised patients, but overall it is considered a
harmless colonizer of the oral cavity [18] They hydrolysed the
Z-YPQ-pNA and Z-LPY-pNA substrates, and cleaved the
highly immunogenic a-gliadin 33-mer peptide after QPQ↓ and
LPY↓ [14]. The LPY↓ speciﬁcity is unique and adds to the post-
proline and post-glutamine activities currently being the focus
of luminal enzyme therapy [19].
The bacterial species identiﬁed in Group II was A. odontol-
yticus HOT-701. Its enzymes also cleaved the substrates Z-
YPQ-pNA and Z-LPY-pNA, mixed gliadins and the 33-mer
peptide. The molecular weight of the enzyme was distinctly
lower than that of the Rothia bacteria. Actinomyces odontolyticus
HOT-701 is typically isolated from patients with advanced
dental caries [20], and has rarely been implicated in bacter-
aemia [21]. It is described as an anaerobic microorganism, but
we could culture it both under aerobic and under anaerobic
conditions. The typing of A. odontolyticus was made based on
16S rDNA analysis. As the level of homology in the 490-bp
sequence after removal of any ambiguous base calls was 98%, it
cannot be excluded that strain PA-20b represents a closely
related Actinomyces subspecies. Therefore we obtained Amer-
ican Type Culture Collection (ATCC) strain 17929 (A. odon-
tolyticus Batty) for validation of the results with isolate PA-20b.
The zymogram results of the ATCC strain were indistinguish-
able from PA-20b, conﬁrming the gluten-degrading capacity of
A. odontolyticus (data not shown). Notably, strain PA-20b
degraded gliadin in gel but not in solution, suggesting that
substrate conformation is an important determinant for
recognition. PA-20b quickly degraded the 33-mer, faster than
the Rothia bacteria. However, the degradation fragments were
stable and of substantial length, given their high retention times
in the HPLC chromatograms. Therefore, PA-20b enzymes
would work optimally in combination with other enzymes to
achieve the full fragmentation of immunogenic gliadin peptides.
The bacteria in group III comprised S. mitis HOT-677 and
Streptococcus sp. HOT-071. Streptococcus mitis HOT-677 is the
second most abundant oral microorganism. It has been
detected on the buccal epithelium, maxillary anterior vestibule,
tongue dorsum, hard and soft palate, tonsils, tooth surfaces
and subgingival plaque [22]. The selection of S. mitis following
the plating approach might have been due to its high
abundance, rather than it being a truly gliadin-degrading
organism. Indeed, it exhibited low gliadin-degrading activities
in gel, and negligible or undetectable activities in solution.
Neither of the streptococcal species cleaved the 33-mer
peptide. Nevertheless, because of its high abundance, S. mitis
could still contribute substantially to the overall gliadin-
degrading capacity in the human mouth.
The bacterium in Group IV was typed as N. mucosa HOT-
682. This is a gram-negative aerobic bacterium that is a non-
pathogenic resident of the oropharynx of humans. As for the
other strains identiﬁed, rare cases of systemic infections with
N. mucosa have been reported [23,24]. Interestingly,
N. mucosa strains hydrolysed three of the ﬁve gliadin-related
tripeptide substrates, but not any of the larger substrates
(33-mer, or intact gliadin, either in gel or in solution).
Given this limited activity, N. mucosa is deemed of less interest
for enzyme isolation and potential exploitation in coeliac
disease.
Lastly, group V comprised the bacterium C. sputigena HOT-
775. This species stood out from the other identiﬁed
microorganisms in being able to cleave all ﬁve gliadin-based
tripeptide substrates. This result demonstrates that a wide
variety of protease speciﬁcities are contained within this single
microorganism. Capnocytophaga sputigena HOT-775 is a gram-
negative oral colonizer. It has been implicated in a number of
infectious diseases, e.g. septicaemia, osteomyelitis, abscesses
and keratitis [25], perhaps, owing to its high and diverse
protease activities (Table 2). Like A. odontolyticus HOT-701,
C. sputigena HOT-775 rapidly cleaved the immunogenic 33-
mer gliadin peptide, grouping this bacterium automatically into
the category of high interest. In contrast to A. odontolyticus
HOT-701, no larger protease-resistant peptides were
observed, indicating extensive fragmentation of the 33-mer
peptide by C. sputigena HOT-775. It can be assumed, but needs
further proof, that immunogenic epitopes would therefore be
neutralized. Neisseria mucosa HOT-682 and C. sputigena HOT-
775 did not cleave intact gliadin, neither in a partly denatured
state in the gel matrix, nor in a native conformation in solution,
TABLE 2. Oral abundance and number of proteases in
selected species
Strain name Group
Approximate
rank abundance
in the oral
cavity (#)a
Number of
known and
putative
peptidasesb
Rothia mucilaginosa HOT-681 I 170 13
Rothia aeria HOT-188 I 221 Unavailable
Actinomyces odontolyticus HOT-701 II 326 41
Streptococcus mitis HOT-677 III 2 19
Streptococcus sp. HOT-071 III 37 Unavailable
Neisseria mucosa HOT-682 IV 64 8
Capnocytophaga sputigena HOT-775 V 166 22
aInformation from Dewhirst et al. [16].
bInformation from www.merops.ac.uk.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, E386–E394
E392 Clinical Microbiology and Infection, Volume 19 Number 9, September 2013 CMI
suggesting that larger substrates are not recognized by their
proteases.
While ingested gluten is a necessary trigger for the
development of coeliac disease, gluten reactivity alone cannot
explain the absence of disease in most subjects with HLA-DQ2
and HLA-DQ8 phenotypes. A prominent role for the gastro-
intestinal microbiome in the switch from tolerance to an
inﬂammatory immune response to gluten is becoming evident
[26]. Recently, this concept was further supported by studies
showing a difference between the developing gut microbiome
in HLA-DQ2+ DQ8+ children of patients with biopsy-proven
coeliac disease [27] and children from healthy mothers [28].
Besides modulating the immune response, our study provides
evidence that the microbiota of the (upper) gastrointestinal
tract may also play a more direct role by degrading toxic gluten
peptides, and perhaps aiding gluten detoxiﬁcation in vivo.
How far the gluten-degrading microorganisms contribute
to gluten digestion in vivo remains to be established. Apart
from their potential physiological effects as natural colonizers
of the upper gastrointestinal tract, the bacteria—and their
enzymes—could also be exploited therapeutically as digestive
aids. Gluten-degrading enzymes from other sources are
already being pursued as adjunctive therapeutics for coeliac
disease [7–13]. Similarly, the gluten-degrading enzymes from
the oral bacteria could be isolated and further pursued as a
pharmaceutical drug, or dietary supplement. The advantage is
that the sources of these enzymes are natural human body-
associated microbes, and most oral bacteria are indeed
harmless residents. Given their tolerated natural colonization
of the upper gastrointestinal tract an alternative approach
would be to develop the gluten-degrading bacteria them-
selves, as probiotic agents, to achieve gluten digestion.
Successful application would require the probiotic to be
effective along the gastrointestinal canal and to be safe when
consumed in larger quantities, aspects that are currently being
addressed.
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